Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bruce Davis joins LeukoDx

This article was originally published in Clinica

Executive Summary

Point-of-care diagnostics company LeukoDx (Towson, Maryland) has appointed Bruce Davis chief scientific officer. Dr Davis is the founder and president of Trilium Diagnostics, which is developing diagnostics assays for clinical cytometry and lab haematology. LeukoDx has also licensed a patent and technology from Trilium regarding quantifying CD64. The latter's CD64 test kits are CE marked for sale in Europe, and awaiting US FDA approval. LeukoDx plans to make CD64 the first biomarker to be used in its disposable test cartridge for diagnosing and monitoring sepsis, which will run on its point-of-care flow cytometry platform. The company is also developing tests for detecting urinary tract infection, and monitoring HIV progression and treatment.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT045216

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel